Table 6.
Pre- and post-vaccination geometric mean concentration and geometric mean concentration ratio for subjects who received wP vaccine
| Assay | Antigen | Geometric mean concentration (n) | ||
|---|---|---|---|---|
| Pre-vaccination GMC | Post-vaccination GMC | GMC ratio | ||
| ECL | PT | 3.9 (36) | 128.7 (36) | 33.25 |
| FHA | 10.1 (33) | 27.1 (31) | 2.69 | |
| FIM | 8.5 (36) | 1213.1 (35) | 142.51 | |
| PRN | 2.1 (36) | 27.5 (36) | 12.79 | |
| GenWay | wP | 9.9 (34) | 15.7 (29) | 1.58 |
| Demeditec | wP | 2.7 (35) | 19.1 (36) | 6.94 |
FHA filamentous hemagglutinin, FIM fimbrial agglutinogen, n number of subjects, PRN pertactin, PT pertussis toxin, wP whole-cell pertussis